MCID: SCL009
MIFTS: 48

Sclerosing Cholangitis malady

Categories: Gastrointestinal diseases, Rare diseases, Liver diseases

Aliases & Classifications for Sclerosing Cholangitis

Aliases & Descriptions for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 14
Cholangitis, Sclerosing 42 69
Primary Sclerosing Cholangitis 69
Fibrosing Cholangitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14268
ICD10 33 K83.0
MeSH 42 D015209
UMLS 69 C0008313

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as cholangitis, sclerosing, is related to hepatitis and bile duct adenocarcinoma, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Allograft rejection and HTLV-I infection. The drugs Vancomycin and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and liver/biliary system

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.9 HLA-B HLA-C HLA-DRB1 TNF
2 bile duct adenocarcinoma 29.8 ALB CD40LG
3 celiac disease 29.6 CD40LG HLA-B TNF
4 uveitis 29.5 BPI CD40LG TNF
5 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.4
6 cholangitis, primary sclerosing 12.2
7 secondary sclerosing cholangitis 12.2
8 igg4-related sclerosing cholangitis 12.1
9 isolated neonatal sclerosing cholangitis 12.0
10 cholangitis 11.1
11 cholangiocarcinoma, susceptibility to 11.0
12 colitis 10.6
13 ulcerative colitis 10.6
14 pancreatitis 10.5
15 inflammatory bowel disease 10.5
16 autoimmune pancreatitis 10.4
17 primary biliary cirrhosis 10.4
18 autoimmune hepatitis 10.3
19 sacral nerve root cysts 10.3 HLA-B HLA-DRB1
20 congenital dyserythropoietic anemia 10.3 ALB TNF
21 crohn's disease 10.3
22 epididymo-orchitis 10.3 HLA-B HLA-C
23 learning disability 10.3 HLA-B HLA-C HLA-DRB1
24 retroperitoneal germ cell neoplasm 10.2 ALB FUT2 HLA-DRB1
25 mirizzi syndrome 10.2 HLA-B HLA-DRB1 TNF
26 anaerobic meningitis 10.2 HLA-B HLA-C HLA-DRB1
27 swine influenza 10.2 HLA-B HLA-DRB1 TNF
28 autosomal dominant intermediate charcot-marie-tooth 10.2 CFTR HLA-DRB1 TNF
29 folinic acid-responsive seizures 10.2 HLA-B HLA-C HLA-DRB1
30 aseptic meningitis 10.2 HLA-B HLA-DRB1 TNF
31 immune deficiency, familial variable 10.2 HLA-B HLA-DRB1
32 anterior corneal pigmentation 10.2 HLA-B HLA-C HLA-DRB1
33 kernicterus due to isoimmunization 10.2 HLA-C HLA-DRB1 TNF
34 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DRB1 TNF
35 orbital osteomyelitis 10.2 HLA-B HLA-C TNF
36 colloid adenoma 10.2 ALB CD40LG
37 rift valley fever 10.2 ALB CFTR TNF
38 colon adenocarcinoma 10.2 ALB FUT2 TNF
39 bickerstaff brainstem encephalitis 10.2 CFTR HLA-B HLA-C HLA-DRB1
40 estrogen excess 10.2 ALB CD40LG
41 nystagmus, congenital motor, autosomal recessive 10.2 CFTR HLA-B HLA-DRB1 TNF
42 liver disease 10.2
43 pseudohypoparathyroidism 10.1 CD40LG HLA-C HLA-DRB1
44 molybdenum cofactor deficiency a 10.1 HLA-B HLA-C HLA-DRB1 TNF
45 human immunodeficiency virus infectious disease 10.1 CD40LG HLA-DRB1 TNF
46 pancreatic signet ring cell adenocarcinoma 10.1 CD40LG HLA-DRB1 TNF
47 endogenous depression 10.1 CD40LG HLA-DRB1 TNF
48 freiberg's disease 10.1 ALB CD40LG
49 immunoglobulin g deficiency 10.1 CD40LG HLA-DRB1 TNF
50 retroperitoneal fibrosis 10.1

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

GenomeRNAi Phenotypes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.8 HLA-B HLA-C CTSG
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.8 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.8 HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.8 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.8 CTSG
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.8 HLA-C CTSG
7 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.8 HLA-B HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.8 CTSG
9 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.8 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.8 HLA-B HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.8 HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.8 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.8 CTSG
14 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.8 HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.8 CTSG
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.8 HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.8 HLA-B HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.8 HLA-B HLA-C
19 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.8 HLA-C

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.28 MST1 NR1I2 TNF ABCB11 ABCB4 ALB

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 1 1404-90-6 441141 14969
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
5
Ofloxacin Approved Phase 4 82419-36-1 4583
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
10 Bile Acids and Salts Phase 4,Phase 2,Phase 1
11 glucocorticoids Phase 4,Phase 1
12 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Hormone Antagonists Phase 4,Phase 1
14 Hormones Phase 4,Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Immunoglobulin G Phase 4,Phase 1,Phase 2
18 Immunoglobulins Phase 4,Phase 2,Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
21 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
22 Antibiotics, Antitubercular Phase 4,Phase 2
23 Antibodies Phase 4,Phase 2,Phase 1
24 Antirheumatic Agents Phase 4,Phase 1,Phase 2
25 Prednisolone acetate Phase 4
26 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Topoisomerase Inhibitors Phase 4
29 Prednisolone hemisuccinate Phase 4
30 Prednisolone phosphate Phase 4
31 Renal Agents Phase 4
32 Methylprednisolone acetate Phase 4
33 Methylprednisolone Hemisuccinate Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Antitubercular Agents Phase 4
36
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 1 128-13-2 31401
37
Bezafibrate Approved Phase 3 41859-67-0 39042
38 Antimetabolites Phase 3,Phase 1,Phase 2
39 Cholagogues and Choleretics Phase 2, Phase 3,Phase 1
40 Hypolipidemic Agents Phase 3,Phase 1,Phase 2
41 Lipid Regulating Agents Phase 3,Phase 1,Phase 2
42
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
43
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
44
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
45
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
46 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 1, Phase 2
48 2-chloro-3'-deoxyadenosine Phase 2
49 Antibodies, Monoclonal Phase 2
50
Curcumin Phase 1, Phase 2 458-37-7 969516

Interventional clinical trials:

(show top 50) (show all 82)
id Name Status NCT ID Phase
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Recruiting NCT02605213 Phase 4
2 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4
3 Leflunomide for Maintenance of Remission in IgG4 Related Disease Recruiting NCT02703194 Phase 4
4 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4
5 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
6 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3
7 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3
8 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
9 The Effect of Bezafibrate on Cholestatic Itch Recruiting NCT02701166 Phase 3
10 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Active, not recruiting NCT01802073 Phase 3
11 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3
12 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2
13 Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2
14 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2
15 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
16 Rituximab in IgG4-related Disease: A Phase 1-2 Trial Completed NCT01584388 Phase 1, Phase 2
17 Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Recruiting NCT01688024 Phase 2
18 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis Recruiting NCT02653625 Phase 2
19 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Recruiting NCT02424175 Phase 1, Phase 2
20 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Recruiting NCT02239211 Phase 2
21 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Recruiting NCT02978339 Phase 1, Phase 2
22 Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Recruiting NCT02943460 Phase 2
23 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2
24 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Active, not recruiting NCT02177136 Phase 2
25 Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis Active, not recruiting NCT02704364 Phase 2
26 A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Not yet recruiting NCT02780752 Phase 1, Phase 2
27 A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH Not yet recruiting NCT02997878 Phase 1, Phase 2
28 Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) Terminated NCT00953615 Phase 2
29 Fenofibrate for PSC Terminated NCT01142323 Phase 1, Phase 2
30 The Value of CT Cholangiography in Primary Sclerosing Cholangitis Withdrawn NCT00588458 Phase 2
31 Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis Completed NCT01456468 Phase 1
32 Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) Completed NCT00955149 Phase 1
33 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Completed NCT01322386 Phase 1
34 Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Completed NCT01088607 Phase 1
35 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1
36 Minocycline in Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1
37 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed NCT01085760 Phase 1
38 Evaluation of DHA for the Treatment of PSC Completed NCT00325013 Phase 1
39 A Pilot Study of Xifaxan to Treat Patients With PSC Completed NCT01695174 Phase 1
40 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT Completed NCT01879735 Phase 1
41 Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging Completed NCT01439620 Phase 1
42 Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Recruiting NCT02137668 Phase 1
43 Genomics of Primary Sclerosing Cholangitis (PSC) Recruiting NCT01161992 Phase 1
44 A Study of HTD1801 in Healthy Subjects Recruiting NCT03099603 Phase 1
45 Treatment of IgG4-Related Disease With Revlimid and Rituximab Recruiting NCT02705638 Phase 1
46 NPD Measurements in PSC Patients Unknown status NCT00476814
47 Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis Unknown status NCT02247622
48 Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy Unknown status NCT01549795
49 Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU) Unknown status NCT01169168
50 Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis Unknown status NCT00160940

Search NIH Clinical Center for Sclerosing Cholangitis

Cochrane evidence based reviews: cholangitis, sclerosing

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

39
Liver, Colon, T Cells, Testes, Thyroid, Neutrophil, Pancreas

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 925)
id Title Authors Year
1
Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. ( 28055006 )
2017
2
Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice. ( 28056490 )
2017
3
A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. ( 28056976 )
2017
4
Updates on primary sclerosing cholangitis. ( 28079751 )
2017
5
Primary biliary cholangitis-primary sclerosing cholangitis in an evolving overlap syndrome: A case report. ( 28089354 )
2017
6
Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. ( 28050039 )
2017
7
Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]. ( 28042931 )
2017
8
CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome. ( 28073151 )
2017
9
Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran. ( 27032493 )
2016
10
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. ( 26864161 )
2016
11
IgG4-related Sclerosing Cholangitis with No Biliary Stricture but Severe Thickening of the Bile Duct Wall. ( 27301508 )
2016
12
Primary Sclerosing Cholangitis. ( 27653566 )
2016
13
IgG4-related sclerosing cholangitis: all we need to know. ( 26817943 )
2016
14
Gut and liver T cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. ( 27647428 )
2016
15
Shifting Paradigms: What Is the True Prevalence and Clinical Course of Primary Sclerosing Cholangitis? ( 27590692 )
2016
16
IgG4+ B-Cell Receptor Clones Distinguish IgG4-Related Disease from Primary Sclerosing Cholangitis and Biliary/Pancreatic Malignancies. ( 27015613 )
2016
17
IgG4-Related Sclerosing Cholangitis. ( 27466792 )
2016
18
An Update on Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. ( 28028930 )
2016
19
The Microbiome and Primary Sclerosing Cholangitis. ( 27997974 )
2016
20
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. ( 27207975 )
2016
21
CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. ( 27630216 )
2016
22
Outcomes of Liver Retransplantation in Patients with Primary Sclerosing Cholangitis. ( 28027592 )
2016
23
Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. ( 27470434 )
2016
24
Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis: a comparison study with dual-energy X-ray absorptiometry. ( 27492220 )
2016
25
Impact of Concurrent Non-IBD Immunological Diseases on the Outcome of Primary Sclerosing Cholangitis. ( 26950311 )
2016
26
Secondary sclerosing cholangitis in a critically ill patient. ( 27190777 )
2016
27
Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. ( 27536366 )
2016
28
Secondary sclerosing cholangitis rapidly leading to liver cirrhosis: a possible post-ICU treatment sequel. ( 26092685 )
2016
29
Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. ( 27002801 )
2016
30
Elevated Serum Bilirubin Level Correlates With the Development of Cholangiocarcinoma, Subsequent Liver Transplantation, and Death in Patients With Primary Sclerosing Cholangitis. ( 26927495 )
2016
31
The evolution of natural history of primary sclerosing cholangitis. ( 28030370 )
2016
32
Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? ( 27587361 )
2016
33
Secondary Sclerosing Cholangitis From Spontaneous Choledochoduodenal Fistula. ( 27670380 )
2016
34
The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report. ( 27876037 )
2016
35
Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis. ( 27127503 )
2016
36
Sclerosing cholangitis and intracranial lymphoma in a child with classical Wiskott-Aldrich syndrome. ( 27566838 )
2016
37
Primary Sclerosing Cholangitis. ( 28002708 )
2016
38
Letter: impact of concomitant autoimmune diseases on the outcome of primary sclerosing cholangitis. ( 27137734 )
2016
39
Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease. ( 26806276 )
2016
40
Alkaline Phosphatase at Diagnosis of Primary Sclerosing Cholangitis and One Year Later: Evaluation of Prognostic Value. ( 26945698 )
2016
41
Primary sclerosing cholangitis: a new cause of distal renal tubular acidosis. ( 27994859 )
2016
42
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. ( 26938805 )
2016
43
Early Peribiliary Hyperenhancement on MRI in Patients with Primary Sclerosing Cholangitis: Significance and Association with the Mayo Risk Score. ( 27472938 )
2016
44
Secondary Sclerosing Cholangitis During Pregnancy. ( 27622193 )
2016
45
Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 27590963 )
2016
46
A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. ( 26966527 )
2016
47
Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. ( 27558072 )
2016
48
Autoanti-C in a patient with primary sclerosing cholangitis and autoimmune hemolytic anemia: a rare presentation. ( 27834483 )
2016
49
Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. ( 27216937 )
2016
50
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: an Update on MR Imaging Findings with Recent Developments. ( 27981308 )
2016

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 ABCB11 ABCB4 BPI CD40LG CFTR CLDN1
2 extracellular exosome GO:0070062 9.7 ABCB11 ABCB4 ALB BPI CFTR CTSG
3 early endosome membrane GO:0031901 9.67 CFTR HLA-B HLA-C
4 recycling endosome membrane GO:0055038 9.54 CFTR HLA-B HLA-C
5 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-B HLA-C HLA-DRB1
6 MHC class I protein complex GO:0042612 9.43 HLA-B HLA-C
7 intercellular canaliculus GO:0046581 9.4 ABCB11 ABCB4
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-B HLA-C HLA-DRB1
9 cell surface GO:0009986 9.17 CD40LG CFTR CTSG HLA-B HLA-C HLA-DRB1
10 integral component of membrane GO:0016021 10.23 ABCB11 ABCB4 BPI CD40LG CFTR CLDN1
11 plasma membrane GO:0005886 10.22 ABCB11 ABCB4 CD40LG CFTR CLDN1 CTSG

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-B HLA-C HLA-DRB1
2 negative regulation of growth of symbiont in host GO:0044130 9.48 CTSG TNF
3 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.46 ABCB11 CFTR
4 xenobiotic transport GO:0042908 9.43 ABCB4 NR1I2
5 antigen processing and presentation GO:0019882 9.43 HLA-B HLA-C HLA-DRB1
6 response to dexamethasone GO:0071548 9.4 ABCB4 CLDN1
7 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.37 HLA-B HLA-C
8 immune response GO:0006955 9.17 BPI CD40LG CTSG HLA-B HLA-C HLA-DRB1
9 drug export GO:0046618 9.16 ABCB4 NR1I2
10 regulation of immunoglobulin secretion GO:0051023 8.96 CD40LG TNF

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 ABCB11 ABCB4 CFTR
2 peptide antigen binding GO:0042605 8.8 HLA-B HLA-C HLA-DRB1

Sources for Sclerosing Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....